| 摘要 |
PROBLEM TO BE SOLVED: To efficiently produce the subject compound useful as a synthetic intermediate for medicines having physiological activities such as a melatonin receptor affinity on an industrial scale of large amounts by using a catalytic amount of a ruthenium-optically active phosphine complex. SOLUTION: The asymmetric hydrogenating reaction of (A) a compound (salt) represented by formula I or II R<1> is H, a hydrocarbon (having a substituent group) or a heterocyclic group (having a substituent group) ; B is H or a group binding through O, N or S; T is a group represented by the formula (CH2 )m [(m) is 1-4]; A-ring may have a substituent group and further may form a condensed ring with one 5- to 6-membered ring} is carried out in the presence of (B) a transition metal-optically active phosphine complex to afford an optically active substance (salt) of a compound represented by formula III (* is asymmetric carbon atom). For example, (R) or (S)-[2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl]}ruthenium diacetate is preferably used as the component B. |
